These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 11874940

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 6. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA.
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E871-83. PubMed ID: 17106061
    [Abstract] [Full Text] [Related]

  • 13. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [Abstract] [Full Text] [Related]

  • 14. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
    Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H, Tominaga M, Sasaki H, Ikeda M, Kubota M, Ishida Y, Hozumi T, Baba S, Uehara M, Shichiri M, Kaneko T.
    Tohoku J Exp Med; 1997 Nov; 183(3):173-83. PubMed ID: 9550126
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group.
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C, Gao Y, Gao X, Li G, Luo B, Shi H, Tian H, Jia P, Lin H, Xing X, Zhao Y, Zhou L.
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
    [Abstract] [Full Text] [Related]

  • 18. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang A, Azen S, Buchanan TA.
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [Abstract] [Full Text] [Related]

  • 19. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
    Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F.
    Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
    [Abstract] [Full Text] [Related]

  • 20. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
    Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM.
    Diabetes Care; 1992 Feb; 15(2):193-203. PubMed ID: 1547676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.